

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. - 18. (Cancelled)

19. (Currently Amended) A method of treating conditions associated with autoimmune disease in a human, said method comprising the step of administering to said human in need thereof an effective amount of ~~the~~an altered antibody comprising a heavy chain and a light chain, wherein the framework regions of said heavy and light chains are derived from at least one selected antibody and the amino acid sequences of the complementarity determining regions of each said chain are derived from a rodent neutralizing monoclonal antibody specific for human interleukin-18 that has a binding affinity characterized by a dissociation constant equal to or less than about  $3.9 \times 10^{-11}$  M of claim ~~13~~.

20. - 26. (Cancelled)

27. (New) The method as claimed in Claim 19, wherein said autoimmune disease is selected from the group of: multiple sclerosis, rheumatoid arthritis, insulin-dependent diabetes, inflammatory bowel disease, and psoriasis.

28. (New) The method as claimed in Claim 19, wherein the altered antibody comprises the heavy chain amino acid sequence of SEQ ID NO:10 and the light chain amino acid sequence of SEQ ID NO:2.

29. (New) The method as claimed Claim 19, wherein the altered antibody comprises an immunoglobulin heavy chain complementarity determining region (CDR), the amino acid sequence of which is isolated and is chosen from the group of:

- (a) SEQ ID NO:12;
- (b) SEQ ID NO:14; and
- (c) SEQ ID NO:16.

30. (New) The method as claimed Claim 19, wherein the altered antibody comprises an immunoglobulin light chain complementarity determining region (CDR), the amino acid sequence of which is isolated and is chosen from the group of:

- (d) SEQ ID NO:4;
- (e) SEQ ID NO:6; and
- (f) SEQ ID NO:8.

31. (New) The method as claimed Claim 19, wherein the altered antibody comprises an immunoglobulin heavy chain complementarity determining region (CDR), the amino acid sequence of which is isolated and is chosen from the group of:

- (g) SEQ ID NO:28;
- (h) SEQ ID NO:30;
- (i) SEQ ID NO:32
- (j) SEQ ID NO:44;
- (k) SEQ ID NO:46; and
- (l) SEQ ID NO:48.

32. (New) The method as claimed Claim 19, wherein the altered antibody comprises an immunoglobulin light chain complementarity determining region (CDR), the amino acid sequence of which is isolated and is chosen from the group of:

- (a) SEQ ID NO:20;
- (b) SEQ ID NO:22;
- (c) SEQ ID NO:24
- (d) SEQ ID NO:36;
- (e) SEQ ID NO:38; and
- (f) SEQ ID NO:40.